2019 Multiple Myeloma Symposium | Q&A with Clifton Mo, MD

2019 Multiple Myeloma Symposium | Q&A with Clifton Mo, MDПодробнее

2019 Multiple Myeloma Symposium | Novel and Next Generation TherapyПодробнее

2019 Multiple Myeloma Symposium | Managing Bone DiseaseПодробнее

2019 Multiple Myeloma Symposium | Symptom ManagementПодробнее

The Evolution of Systemic Therapy for Newly Diagnosed Multiple Myeloma, Dana-Farber Cancer InstituteПодробнее

2019 Multiple Myeloma Symposium | Diagnosis, Prognosis & RiskПодробнее

2019 Multiple Myeloma Symposium | Cellular ImmunotherapyПодробнее

2019 Multiple Myeloma Symposium | Current & Future TreatmentПодробнее

COVID-19 and Multiple Myeloma: Clifton Mo, MDПодробнее

2019 Multiple Myeloma Symposium | Smoldering Multiple MyelomaПодробнее

Continued Evolution of Therapy for Patients with Newly Diagnosed Multiple MyelomaПодробнее

Multiple Myeloma Symposium: Future of Treatment | Dana-Farber Cancer InstituteПодробнее

Multiple Myeloma Symposium: Q & A with Faculty| Dana-Farber Cancer InstituteПодробнее

Lenalidomide vs Observation for Asymptomatic High-Risk Smoldering Multiple MyelomaПодробнее

New Directions in Treating Multiple Myeloma in the Era of Novel AgentsПодробнее

Multiple Myeloma Symposium: Emerging Treatment Options | Dana-Farber Cancer InstituteПодробнее

Multiple Myeloma: Bone Health | Dana-Farber Cancer InstituteПодробнее

Multiple Myeloma Symposium: Bone Health | Dana-Farber Cancer InstituteПодробнее

Multiple Myeloma Symposium: A Patient's Perspective | Dana-Farber Cancer InstituteПодробнее

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее